DERM Stock Risk & Deep Value Analysis
Journey Medical Corp
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About DERM Stock
We analyzed Journey Medical Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DERM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is DERM Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
High
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for DERM?
- ⚠
DFD-29 Complete Response Letter (CRL) from FDA
- ⚠
Slower-than-expected DFD-29 commercial uptake post-approval
- ⚠
New competitive therapies entering the rosacea market
Unlock DERM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Journey Medical Corp (DERM) Do?
Market Cap
$195.61M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
41
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Visit Journey Medical Corp WebsiteIs DERM Stock Undervalued?
Unlock the full AI analysis for DERM
Get the complete DVR score, risk analysis, and more
Does DERM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is primarily derived from patent protection for DFD-29, which provides a period of market exclusivity, estimated for 10-15 years post-approval. This allows time to build market share and brand recognition.
Moat Erosion Risks
- •Expiration of DFD-29 patents and subsequent generic competition.
- •Introduction of superior or significantly cheaper new treatments for rosacea.
- •Challenges in establishing DFD-29's brand and market acceptance.
DERM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive DERM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated May 2026)
- •DFD-29 PDUFA date (estimated Q3 2026, e.g., August 2026)
Medium-Term (6-18 months)
- •DFD-29 Commercial Launch (expected late 2026 / early 2027)
- •Initial DFD-29 sales figures and market penetration updates
Long-Term (18+ months)
- •Significant market share capture in the rosacea treatment segment
- •Potential label expansion for DFD-29 or pipeline development
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DERM (Journey Medical Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
